Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Depigoid rush vs conventional regimen
2005-001584-66Phase 3Completed
- Sponsor
- LETI Pharma
- Start
- Jul 2005
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of Depigoid in allergic rhinitis (AR), allergic rhinoconjunctivitis (ARC), house dust mite allergy and 2 more (2 arms), sponsored by LETI Pharma. Primary endpoint: Proportion of patients reaching the maintenance treatment phase. Started Jul 2005; status: completed.
02
Drugs
Depigoid
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)house dust mite allergygrass pollen allergyTree Pollen Allergy (TPA)
Beyond the preview
Go deeper on 2005-001584-66.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-001584-66.